β1 Integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells

Circulation

Volumn 97, Issue 9, 1998, Pages 907-915

  Stouffer, George A ^a,d   Hu, Zhaoyong ^a   Sajid, Mansoor ^a   Li, Husong ^a   Jin, Guifang ^a   Nakada, Marian T ^b   Hanson, Stephen R ^c   Runge, Marschall S ^a  

^a Sealy Ctr for Molecular Cardiology   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Angioplasty; Muscle, smooth; Receptors; Signal transduction

Indexed keywords

ABCIXIMAB; IMMUNOGLOBULIN G; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; THROMBIN; THROMBOSPONDIN; ANTITHROMBOCYTIC AGENT; BETA3 INTEGRIN; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN KINASE (CALCIUM,CALMODULIN);

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; BABOON; BALLOON CATHETER; BLOOD VESSEL INJURY; BRACHIAL ARTERY; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; SERUM; SMOOTH MUSCLE FIBER; THROMBOCYTE; ANIMAL; CELL DIVISION; CYTOLOGY; DRUG EFFECT; INJURY; METABOLISM; PAPIO; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, BALLOON; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; BRACHIAL ARTERY; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL DIVISION; CELLS, CULTURED; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTEGRIN BETA3; INTEGRINS; MALE; MUSCLE, SMOOTH, VASCULAR; PAPIO; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS; SIGNAL TRANSDUCTION; THROMBIN; THROMBOSPONDINS; UP-REGULATION;

EID: 0032502061     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.9.907     Document Type: Article

References (46)

1. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT. on behalf of the EPIC Investigators: Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
2. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ, van Dijk R, van den Bos AA, Umans VA, Fox KAA, Close P, Deckers JW, for the Helvetica Investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1995;333:757-763.
3. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988;318:1714-1719.
4. White CW, Chaitman B, Knudtson ML, Chisholm RJ, and the Ticlopidine Study Group. Antiplatelet agents are effective in reducing the acute ischemic complications of angioplasty but do not prevent restenosis: results from the ticlopidine trial. Coron Artery Dis. 1991;2:757-767.
5. Knudtson ML, Flintoft VF, Roth DL, Hansen JL, Duff HJ. Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1990;15:691-697.
6. Gershlick AH, Spriggins D, Davies SW, Syndercombe Court YD, Timmins J, Timmis AD, Rothman MT, Layton C, Balcon R. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial. Br Heart J. 1994;71:7-15.
7. Serruys PW, Rutsch W, Heyndrickx GR, Danchin N, Mast EG, Wijns W, Rensing BJ, Vos J, Stibbe J. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. Circulation. 1991;84:1568-1580.
8. Serruys PW, Klein W, Tijssen JP, Rutsch W, Heyndrickx GR. Emanuelsson H, Ball SG, Decoster O, Schroeder E, Liberman H, Eichhorn E, Willerson JT, Anderson HV, Khaja F, Alexander RW, Baim D, Melkert R, van Oene JC, Van Gool R. Evaluation of ketanserin in the prevention of restenosis after percutaneous coronary angioplasty. Circulation. 1993;88:1588-1601.
9. Cheresh DA. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci U S A. 1987;84:6471-6475.
10. 3 integrin expression in normal and atherosclerotic artery. Circ Res. 1995;77:1129-1135.
11. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. J Clin Invest. 1995;95:713-724.
12. Brown SL, Lundgren CH, Nordt T, Fujii S. Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis. Cardiovasc Res. 1994;28:1815-1820.
13. Okazaki H, Majesky MW, Harker LA, Schwartz SM. Regulation of platelet-derived growth factor ligand and receptor gene expression by α-thrombin in vascular smooth muscle cells. Circ Res. 1992;71:1285-1293.
14. Santoro SA, Frazier WA. Isolation and characterization of thrombospondin. Methods Enzymol. 1987;144:438-446.
15. Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GP IIb/IIIa receptor: correlation with bleeding time, platelet aggregation, and blockade of GP IIb/IIIa receptors. Circulation. 1989;80:1766-1774.
16. 3 integrin receptors: a potential mechanism for the prevention of restenosis. J Am Coll Cardiol. 1997;29:243A. Abstract.
17. Miano JM, Vlasic N, Tota RR, Stemerman MB. Smooth muscle cell immediate-early gene and growth factor activation follows vascular injury. Arterioscler Thromb. 1993;13:211-219.
18. Raugi GJ, Mullen JS, Bark DH, Okada T, Mayberg MR. Thrombospondin deposition in rat carotid artery injury. Am J Pathol. 1990;137:179-185.
19. Lawler J, Weinstein R, Hynes RO. Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors. J Cell Biol. 1988;107:2351-2361.
20. Graves LM, Bornfeldt KE, Argast GM, Krebs EC, Kong X, Lin TA, Lawrence JC. cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells. Proc Natl Acad Sci U S A. 1995;92:7222-7226.
21. Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 1991;84:232-243.
22. Ferns GAA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129-1132.
23. Vu T, Hung D, Wheaton V, Coughlin S. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068.
24. Williams LT. Signal transduction by the platelet-derived growth factor receptor. Science. 1989;243:1564-1570.
25. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983;72:325-338.
26. Wight TN, Raugi GJ, Mumby SM, Bornstein P. Light microscopic immunolocation of thrombospondin in human tissues. J Histochem Cytochem. 1985;33:295-302.
27. Majack RA, Cook S, Bornstein P. Control of smooth muscle cell growth by components of the extracellular matrix: autocrine role for thrombospondin. Proc Natl Acad Sci U S A. 1986;83:9050-9054.
28. 3 function through integrin-associated peptide. J Cell Biol. 1996;135:533-544.
29. Yabkowitz R, Mansfield PJ, Ryan US, Suchard SJ. Thrombospondin mediates migration and potentiates platelet-derived growth factor-dependent migration of calf pulmonary artery smooth muscle cells. J Cell Physiol. 1993;157:24-32.
30. Mikhailenko I, Kounnas MZ, Strickland DK. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates the cellular internalization and degradation of thrombospondin. J Biol Chem. 1996;270:9543-9549.
31. Godyna S, Liau G, Popa I, Stefansson S, Argraves WS. Identification of the low density lipoprotein receptor-related protein (LRP) as an endocytic receptor for thrombospondin-1. J Cell Biol. 1995;129:1403-1410.
32. Silverstein RL, Baird M, Lo SK, Yesner LM. Sense and antisense cDNA transfection of CD36 (glycoprotein IV) in melanoma cells. J Biol Chem. 1992;267:16607-16612.
33. 3, integrin with a small peptide antagonist GpenGR GDSPCA. J Vasc Surg. 1994;19:125-134.
34. 3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc Natl Acad Sci U S A. 1996;93:2482-2487.
35. Yue TL, McKenna PJ, Ohlstein EH, Farach-Carson MC, Butler WT, Johanson K, McDevitt P, Feuerstein GZ, Stadel JM. Osteopontin-stimulated vascular smooth muscle cell migration is mediated by β3 integrin. Exp Cell Res. 1994;214:459-464.
36. 1 integrin receptors by human vascular smooth muscle cells. Am J Pathol. 1994;145:1070-1081.
37. Janat MF, Argraves WS, Liau G. Regulation of vascular smooth muscle cell integrin expression by transforming growth factor β1 and by platelet-derived growth factor-BB. J Cell Physiol. 1992;151:588-595.
38. Owens GK, Geisterfer AA, Yang YW, Komoriya A. Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol. 1988;107:771-780.
39. Stouffer GA, Owens GK, TGF-β promotes proliferation of cultured SMC via both PDGF-AA-dependent and PDGF-AA-independent mechanisms. J Clin Invest. 1994;93:2048-2055.
40. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science. 1995;268:233-239.
41. Yamada KM, Miyamoto S. Integrin transmembrane signaling and cytoskeletal control. Curr Opin Cell Biol. 1995;7:681-689.
42. Cobb BS, Schaller MD, Horng-Leu Z, Parsons JT. Stable association of pp60src and p59fyn with the focal adhesion-associated protein tyrosine kinase, pp125FAK. Mol Cell Biol. 1994;14:147-155.
43. Kawamoto S, Adelstein RS. Characterization of myosin heavy chains in cultured aorta smooth muscle cells. J Biol Chem. 1987;262:7282-7288.
44. Rovner AS, Murphy RA, Owens GK. Expression of smooth muscle and nonmuscle myosin heavy chains in cultured vascular smooth muscle cells. J Biol Chem. 1986;261:14740-14745.
45. Grainger DJ, Hesketh TR, Metcalfe JC, Weissberg PL. A large accumulation of non-muscle myosin occurs at first entry into M phase in rat vascular smooth-muscle cells. Biochem J. 1991;277:145-151.
46. Simons M, Rosenberg RD. Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ Res. 1992;70:835-843.